Disitamab vedotin is an ADC consisting of an anti-HER2 mAb and the antitubulin molecule monomethyl auristatin E. This agent has demonstrated safety and potent antitumor activity in a phase I trial in patients with advanced HER2-positive GC [76]. This evidence concerns the gene ERBB2 and gastric cancer.